NEW YORK (GenomeWeb News) – Fluidigm reported after the close of the market on Thursday a 33 percent increase in its fourth quarter revenues that included a 47 percent spike in consumables revenues.

For the three months ended Dec. 31, 2013 the firm recorded $20.9 million in total revenues, up from $15.7 million in Q4 2012. On average, analysts expected revenues of $20.7 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.